CTOP acetate NEW
| Price | $227 | $677 | $997 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-11 |
Product Details
| Product Name: CTOP acetate | Purity: 99.87% |
| Supply Ability: 10g | Release date: 2026/05/11 |
Product Introduction
Bioactivity
| Name | CTOP acetate |
| Description | CTOP acetate is a somatostatin analogue and a μ-opioid receptor antagonist. |
| In vitro | CTOP acetate increased a K+ conductance with an EC50 of 560 nM. The K+ currents induced by high concentrations of CTOP acetate desensitized to 42% of the initial maximum after prolonged superfusion (t1/2 = 247 sec). In the presence of fully desensitized CTOP acetate responses, somatostatin (1 microM) still produced near-maximal K+ currents; i.e., there was no cross-desensitization, which suggests that CTOP acetate might act on a receptor distinct from somatostatin receptors. However, the converse did not apply; high concentrations of CTOP acetate (30 microM) did not produce any additional current in the presence of desensitized somatostatin responses[2]. |
| In vivo | Intracerebroventricular (i.c.v.) administration of CTOP acetate antagonized the analgesic effect of morphine in a dose-dependent manner, as measured by the heat-irradiant (tail-flick) method. CTOP acetate was more effective than naloxone in inhibiting analgesia on a molar basis. CTOP acetate also antagonized the acute morphine-induced hypermotility. CTOP acetate caused withdrawal hypothermia and a loss of body weight in morphine-dependent animals. After the development of morphine-induced chronic dependence, CTOP acetate administered i.c.v. caused a dose-dependent loss of body weight and hypothermia, and was about 10-400 times more potent than naloxone. CTOP acetate administered alone to drugnaive mice did not cause antinociception, changes in body weight or body temperature[1]. |
| Storage | Store at low temperature,Keep away from moisture Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | μ-opioid receptor | OpioidReceptor | Opioid Receptor | CTOP acetate |
| Inhibitors Related | Docusate sodium | Bevenopran | Mirtazapine | Matrine | (-)-Menthol | Cuminaldehyde | Progesterone | Naltrexone hydrochloride | Cebranopadol | BTRX-335140 | Bisacodyl | Mianserin hydrochloride |
| Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | Neurotransmitter Receptor Compound Library | Peptide Compound Library | Inhibitor Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP2Y
|
Shaanxi Xianhe Biotech Co., Ltd
|
2026-06-23 | ||
|
VIP3Y
|
Chongqing Zhihe Biopharmaceutical Co., Ltd.
|
2026-06-29 | ||
| $44.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-06-02 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY